Home Newsfeeds Stephens & Co. Reinstates Overweight on Glaukos, Announces $69 Price Target

Stephens & Co. Reinstates Overweight on Glaukos, Announces $69 Price Target

Stephens & Co. analyst George Sellers reinstates Glaukos (NYSE:GKOS) with a Overweight and announces $69 price target.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Stephens & Co. analyst George Sellers reinstates Glaukos (NYSE:GKOS) with a Overweight and announces $69 price target.

Coinbase to Benefit from SEC’s Bitcoin ETF Approvals – Analyst Expects Favorable Q4

By Anusuya Lahiri

January 11, 4:32 PM

Wedbush analyst Moshe Katri maintained Coinbase Global Inc (NASDAQ: COIN) with an Outperform and raised the

COIN

WhatsApp Jumps On Original Content Bandwagon With Movie Starring NBA’s ‘Greek Freak’

By Shivdeep Dhaliwal

September 15, 5:43 AM

WhatsApp, the mobile messaging platform from Meta Platforms Inc (NASDAQ: META), has shared a trailer for a short film based on the story of National Basketball Association player Giannis Antetokounmpo.

Germfree And Orgenesis Announce Asset Purchase And Strategic Partnership Intended To Revolutionize Cell And Gene Therapy Through Decentralized Production And Global Accessibility

By Benzinga Newsdesk

April 10, 12:01 PM

Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (NASDAQ:ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and

ORGS

Analyst Ratings

Evaluating PagerDuty: Insights From 5 Financial Analysts

By Benzinga Insights

June 12, 10:00 AM

5 analysts have shared their evaluations of PagerDuty (NYSE:PD) during the recent three months, expressing a mix of…

Stephens & Co. Reinstates Overweight on Glaukos, Announces $69 Price Target

Related Posts

Coinbase to Benefit from SEC’s Bitcoin ETF Approvals – Analyst Expects Favorable Q4

WhatsApp Jumps On Original Content Bandwagon With Movie Starring NBA’s ‘Greek Freak’

Germfree And Orgenesis Announce Asset Purchase And Strategic Partnership Intended To Revolutionize Cell And Gene Therapy Through Decentralized Production And Global Accessibility

Evaluating PagerDuty: Insights From 5 Financial Analysts